Cargando…

Targeting c‐met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma

Hepatocyte growth factor (HGF)/c‐met pathway activation has been implicated in the pathogenesis of multiple myeloma (MM), and blocking this pathway has been considered a rational therapeutic strategy for treating MM. Aptamers are single‐stranded nucleic acid molecules that fold into complex 3D struc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yibin, Gao, Hongmei, Zhou, Weihua, Sun, Sunming, Zeng, Yayue, Zhang, Hui, Liang, Long, Xiao, Xiaojuan, Song, Jianhui, Ye, Mao, Yang, Yujia, Zhao, Jingfeng, Wang, Zi, Liu, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237600/ https://www.ncbi.nlm.nih.gov/pubmed/30353654 http://dx.doi.org/10.1111/jcmm.13870

Ejemplares similares

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

GTN057, a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c‐MET tyrosine kinase
por: Okayama, Mikio, et al.
Publicado: (2023)

Origin and evolution of plexins, semaphorins, and Met receptor tyrosine kinases
por: Junqueira Alves, Chrystian, et al.
Publicado: (2019)

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
por: Zhang, Yazhuo, et al.
Publicado: (2018)

Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
por: Zhao, Yuanyuan, et al.
Publicado: (2015)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
por: Demkova, Lucia, et al.
Publicado: (2018)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
por: Ribatti, Domenico
Publicado: (2010)

Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase
por: Fernandes, Marie, et al.
Publicado: (2019)

Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma
por: Koo, Karen, et al.
Publicado: (2023)

Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase
por: Cerchia, Laura, et al.
Publicado: (2005)

Cell Surface Labeling and Detection of Protein Tyrosine Kinase 7 via Covalent Aptamers
por: Albright, Savannah, et al.
Publicado: (2023)

Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering
por: Li, Wenjing, et al.
Publicado: (2019)

GDNF promotes tubulogenesis of GFRα1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase
por: Popsueva, Anna, et al.
Publicado: (2003)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein
por: Li, Hui, et al.
Publicado: (2019)

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
por: Welsh, James W, et al.
Publicado: (2009)

A new synaptic player leading to autism risk: Met receptor tyrosine kinase
por: Judson, Matthew C., et al.
Publicado: (2011)

c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2015)

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma
por: Catenacci, Daniel V. T., et al.
Publicado: (2016)

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase
por: Yao, Hang-Ping, et al.
Publicado: (2021)

The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis
por: Passelli, Katiuska, et al.
Publicado: (2022)

Retraction: Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase
por: Cerchia, Laura, et al.
Publicado: (2015)

Aptamer‐targeted DNA nanostructures with doxorubicin to treat protein tyrosine kinase 7‐positive tumours
por: Liu, Mengting, et al.
Publicado: (2018)

A Novel Regulatory Mechanism of Map Kinases Activation and Nuclear Translocation Mediated by Pka and the Ptp-Sl Tyrosine Phosphatase
por: Blanco-Aparicio, Carmen, et al.
Publicado: (1999)

Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
por: van Leeuwen, Roelof W. F., et al.
Publicado: (2017)

Aptamers Binding to c-Met Inhibiting Tumor Cell Migration
por: Piater, Birgit, et al.
Publicado: (2015)

The Met receptor tyrosine kinase prevents zebrafish primary motoneurons from expressing an incorrect neurotransmitter
por: Tallafuss, Alexandra, et al.
Publicado: (2008)

CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
por: Tan, Yi-Hung Carol, et al.
Publicado: (2010)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors
por: Mekki, Meriem Sarah, et al.
Publicado: (2018)

Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas
por: Lüttich, Lina, et al.
Publicado: (2021)

MET Receptor Tyrosine Kinase Regulates Lifespan Ultrasonic Vocalization and Vagal Motor Neuron Development
por: Kamitakahara, Anna K., et al.
Publicado: (2021)

An mTOR feedback loop mediates the ‘flare’ (‘rebound’) response to MET tyrosine kinase inhibition
por: Altintas, D. M., et al.
Publicado: (2023)

HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer
por: Fan, Gaofeng, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_34drabc0e6f0fl56bmeqcl23br